Non-selective cholecystokinin (CCK) antagonist. Inhibits CCK-stimulated amylase secretion and prevents CCK-induced 2-deoxyglucose uptake in mouse pancreatic acini. Blocks growth of HT29 colon carcinoma cells in response to gastrin 17 treatment. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini.
Iwamoto et al.
Effects of gastrin, proglumide, loxiglumide and L-365,260 on growth of human colon carcinoma cells.
Mauss et al.
Anticancer Res., 1994;14:215
Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists.
Hahne et al.